Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Atossa Therapeutics (GB:0HJ7)
LSE:0HJ7
RESEARCH TOOLSreports
Atossa Therapeutics (0HJ7) Share Price & Analysis
0 Followers
0HJ7 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Atossa Therapeutics News
Options Prices
Currently, No data available
---
Ownership Overview
7.44% Insiders
5.69% Mutual Funds
4.44% Other Institutional Investors
82.43% Public Companies and
Individual Investors
0HJ7 FAQ
What was Atossa Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Atossa Therapeutics’s market cap?
Currently, no data Available
When is Atossa Therapeutics’s upcoming earnings report date?
Atossa Therapeutics’s upcoming earnings report date is May 14, 2024 which is in 20 days.
How were Atossa Therapeutics’s earnings last quarter?
Atossa Therapeutics released its earnings results on Apr 01, 2024. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.065 by $0.005.
Is Atossa Therapeutics overvalued?
According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued.
Does Atossa Therapeutics pay dividends?
Atossa Therapeutics does not currently pay dividends.
What is Atossa Therapeutics’s EPS estimate?
Atossa Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Atossa Therapeutics have?
Atossa Therapeutics has 125,304,060 shares outstanding.
What happened to Atossa Therapeutics’s price movement after its last earnings report?
Atossa Therapeutics reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.065. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Atossa Therapeutics?
Among the largest hedge funds holding Atossa Therapeutics’s share is Graham Capital Management, L.P.. It holds Atossa Therapeutics’s shares valued at N/A.
---
Atossa Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (― Upside)
$4.00 (― Upside)
Blogger Sentiment
Bullish
GB:0HJ7 Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $44.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
84.13%
12-Months-Change
Fundamentals
Return on Equity
-28.80%
Trailing 12-Months
Asset Growth
-22.08%
Trailing 12-Months
Company Description
Atossa Therapeutics
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
---
0HJ7 Earnings Call
Q2 2023
0:00 / 0:00
---
0HJ7 Stock 12 Months Forecast
Average Price Target
―Atossa Therapeutics
―
Benitec Biopharma
―
Anavex Life Sciences
―
Traws Pharma
―
Eton Pharmaceuticals
―
Best Analysts Covering 0HJ7
1 Year
1 Year Success Rate
8/9 ratings generated profit
1 Year Average Return
+41.61%
reiterated a buy rating 16 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +41.61% per trade.
---